Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975787 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT06975787 is a Phase 1 study that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT06975787, a Phase 1 study, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Interventions
- DRUG Odronextamab
- DRUG Vonsetamig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2029-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06975787
The ClinicalTrials.gov registry entry for NCT06975787 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Odronextamab is the first listed.
NCT06975787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06975787 about?
NCT06975787 is a clinical study titled "Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis". This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, call...
What is the current status of trial NCT06975787?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-12-22. Estimated completion is 2029-09-09.
What interventions are being tested in trial NCT06975787?
The interventions under investigation include: Odronextamab (DRUG), Vonsetamig (DRUG).
Who is sponsoring clinical trial NCT06975787?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.